CHAI has developed this memo to lay out information for national HIV programs considering the introduction of pediatric dolutegravir 10 mg dispersible, scored tablets, a newly available generic formulation of DTG that the World Health Organization recommends as the preferred first-line antiretroviral therapy for children living with HIV who are at least 4 weeks of age and weigh at least 3 and up to 20kg.
Comments